GNU201 / Gnubiotics - LARVOL DELTA

Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies against Solid Tumors (Businesswire) - "Gnubiotics Sciences...announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well as contributions from Gnubiotics....The sponsored project will advance GNU201 and GNU101, as potential first-in-class immunotherapeutics that steer immune responses to control growth in solid tumors expressing altered O-glycan profiles thus responding to a critical need in non-responding patients. The multi-year project which will include dose-finding and key translational studies, forms a core part of a broader preclinical development plan that will support an Investigational New Drug Application (IND)."

Financing • Licensing / partnership • Oncology • Solid Tumor